Cite
MLA Citation
A. Zeidan et al.. “A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure.” Leukemia research, vol. 55, n.d., pp. S43–. http://access.bl.uk/ark:/81055/vdc_100045920464.0x000025